DK2209375T3 - Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf - Google Patents

Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf

Info

Publication number
DK2209375T3
DK2209375T3 DK08836018.5T DK08836018T DK2209375T3 DK 2209375 T3 DK2209375 T3 DK 2209375T3 DK 08836018 T DK08836018 T DK 08836018T DK 2209375 T3 DK2209375 T3 DK 2209375T3
Authority
DK
Denmark
Prior art keywords
parp
relations
preparations
inhibitor
procedures
Prior art date
Application number
DK08836018.5T
Other languages
English (en)
Inventor
Ling Wei
Weizheng Xu
Greg Delahanty
Jie Zhang
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40526672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2209375(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Application granted granted Critical
Publication of DK2209375T3 publication Critical patent/DK2209375T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08836018.5T 2007-10-03 2008-10-02 Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf DK2209375T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97711507P 2007-10-03 2007-10-03
PCT/US2008/078606 WO2009046205A1 (en) 2007-10-03 2008-10-02 Parp inhibitor compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
DK2209375T3 true DK2209375T3 (da) 2014-10-06

Family

ID=40526672

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08836018.5T DK2209375T3 (da) 2007-10-03 2008-10-02 Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf

Country Status (27)

Country Link
US (3) US8236802B2 (da)
EP (2) EP2209375B1 (da)
JP (1) JP5439380B2 (da)
KR (1) KR101596526B1 (da)
CN (1) CN102083314B (da)
AU (1) AU2008308664B2 (da)
BR (1) BRPI0820518B1 (da)
CA (1) CA2700903C (da)
CL (1) CL2010000320A1 (da)
CY (1) CY1115747T1 (da)
DK (1) DK2209375T3 (da)
ES (1) ES2504690T3 (da)
HR (1) HRP20140853T1 (da)
IL (1) IL204776A (da)
JO (1) JO3170B1 (da)
MX (1) MX2010003564A (da)
MY (1) MY155237A (da)
NZ (1) NZ585012A (da)
PL (1) PL2209375T3 (da)
PT (1) PT2209375E (da)
RU (1) RU2485122C2 (da)
SG (1) SG185272A1 (da)
SI (1) SI2209375T1 (da)
TW (1) TWI426912B (da)
UA (1) UA99483C2 (da)
WO (1) WO2009046205A1 (da)
ZA (1) ZA201002317B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
CN104478875B (zh) * 2008-08-06 2017-04-12 麦迪韦逊科技有限公司 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US9359605B2 (en) * 2011-03-11 2016-06-07 Sarissa Inc. Method of treating cancer by inhibition of DNA repair proteins
SG2014014294A (en) * 2011-04-11 2014-06-27 Abbvie Inc Parp inhibitors for the treatment of cipn
EP2710142B1 (en) 2011-05-18 2017-04-26 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of cancer aggressiveness and genetic instability
EP2731942B1 (en) * 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
BR112014015152A2 (pt) * 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
CN104945406B (zh) * 2015-05-25 2017-10-10 苏州康润医药有限公司 氮杂非那烯‑3‑酮的衍生物、其制备方法及其作为parp抑制剂的应用
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US12121518B2 (en) * 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
AU2019373416A1 (en) 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
US12479830B2 (en) * 2019-10-10 2025-11-25 Esteve Pharmaceuticals, S.A. Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021249996A1 (en) 2020-06-08 2021-12-16 Oncology Venture ApS Compositions comprising 2x-121 and methods for treating coronavirus infection
CN114053276B (zh) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 一种parp抑制剂tsl-1502中间体tsl-1502m的用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US5950784A (en) 1997-09-03 1999-09-14 Yang; Shu-Chiung C. Hub structural improvement
CA2332279A1 (en) 1998-05-15 1999-11-25 Jia-He Li Carboxamide compounds, compositions, and methods for inhibiting parp activity
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
JP2006527235A (ja) * 2003-06-10 2006-11-30 エフ．ホフマン−ラ　ロシュ　アーゲー １，３，４−トリアザフェナレンおよび１，３，４，６−テトラアザフェナレン誘導体
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
DE602005011308D1 (de) 2004-08-04 2009-01-08 Phosphonics Ltd Substituierte organopolysiloxane und ihre verwendung
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
US7981887B2 (en) 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
JP2013531007A (ja) 2010-07-08 2013-08-01 ワイス・エルエルシー 皮膚障害の治療に有用な新規キノリンエステル

Also Published As

Publication number Publication date
TW200932239A (en) 2009-08-01
US8236802B2 (en) 2012-08-07
AU2008308664A1 (en) 2009-04-09
ES2504690T3 (es) 2014-10-08
CA2700903A1 (en) 2009-04-09
AU2008308664B2 (en) 2014-07-17
EP2209375A1 (en) 2010-07-28
PL2209375T3 (pl) 2014-12-31
BRPI0820518A2 (pt) 2020-01-14
JP5439380B2 (ja) 2014-03-12
ZA201002317B (en) 2013-09-25
RU2485122C2 (ru) 2013-06-20
US8894989B2 (en) 2014-11-25
KR101596526B1 (ko) 2016-02-22
EP2209375B1 (en) 2014-08-27
CY1115747T1 (el) 2017-01-25
EP2842956A1 (en) 2015-03-04
IL204776A (en) 2015-09-24
CN102083314B (zh) 2014-04-30
RU2010117397A (ru) 2011-11-10
JP2010540655A (ja) 2010-12-24
HRP20140853T1 (hr) 2014-10-24
IL204776A0 (en) 2010-11-30
US20150141429A1 (en) 2015-05-21
UA99483C2 (ru) 2012-08-27
BRPI0820518B1 (pt) 2021-09-28
KR20100100771A (ko) 2010-09-15
MY155237A (en) 2015-09-30
US20130011365A1 (en) 2013-01-10
JO3170B1 (ar) 2017-09-20
SG185272A1 (en) 2012-11-29
NZ585012A (en) 2012-06-29
US20090098084A1 (en) 2009-04-16
HK1146792A1 (en) 2011-07-15
CL2010000320A1 (es) 2011-03-11
CN102083314A (zh) 2011-06-01
CA2700903C (en) 2017-05-30
TWI426912B (zh) 2014-02-21
MX2010003564A (es) 2010-09-10
EP2209375A4 (en) 2011-03-09
WO2009046205A1 (en) 2009-04-09
PT2209375E (pt) 2014-10-08
SI2209375T1 (sl) 2014-12-31

Similar Documents

Publication Publication Date Title
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2217577T3 (da) Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
DK2320911T3 (da) Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK2120591T3 (da) Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK3614595T3 (da) Fremgangsmåde og indretning til forbedrede statusrapporter
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
IL243932A0 (en) Certain chemical entities, compositions and methods
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2162402T3 (da) Membranbåret biofilmanordning og fremgangsmåde
IL230076A0 (en) Certain chemical entities, compositions and methods
DK2219726T3 (da) Medicinsk elektrode, elektrodebundt og elektrodebundt-sæt
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
BRPI0821276A2 (pt) Produto, e, uso do produto
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2337837T3 (da) Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2192933T3 (da) Materialer til oftalmologisk og ortorhinolaryngologisk anordning